Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Decreases By 22.7%

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 165,200 shares, a decrease of 22.7% from the March 31st total of 213,800 shares. Based on an average trading volume of 81,400 shares, the short-interest ratio is presently 2.0 days. Approximately 0.6% of the shares of the stock are short sold.

Senti Biosciences Stock Up 4.1 %

Senti Biosciences stock traded up $0.01 during mid-day trading on Friday, hitting $0.29. 44,490 shares of the company were exchanged, compared to its average volume of 64,939. Senti Biosciences has a 1-year low of $0.27 and a 1-year high of $1.10. The business has a fifty day moving average of $0.38 and a 200 day moving average of $0.41. The company has a market capitalization of $13.27 million, a PE ratio of -0.18 and a beta of 2.96.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative return on equity of 74.59% and a negative net margin of 2,692.82%. Research analysts expect that Senti Biosciences will post -1 earnings per share for the current year.

Institutional Trading of Senti Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. 8VC GP I LLC acquired a new stake in shares of Senti Biosciences in the 4th quarter valued at about $1,675,000. ARK Investment Management LLC raised its position in Senti Biosciences by 7.9% in the 4th quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock valued at $1,300,000 after buying an additional 143,785 shares during the last quarter. Finally, TD Asset Management Inc lifted its stake in Senti Biosciences by 88.4% in the 3rd quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock valued at $102,000 after acquiring an additional 113,172 shares in the last quarter. 25.73% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.